Jasper Therapeutics, Inc., a biotech company, plans to launch a public offering to sell shares of its common stock or pre-funded warrants, targeting to raise funds for the development of briquilimab, an antibody therapy for mast cell driven diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The proceeds will be used for advancing its preclinical and clinical programs for briquilimab and for general corporate purposes, including capital expenditures and administrative expenses. The offering is subject to market conditions, and the exact size or completion date is uncertain. No specific numbers related to the offer size or financial goals were provided in the article.